

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 9/00, C07H 7/02, A61K 31/70, 38/14	A1	(11) International Publication Number: WO 96/29339 (43) International Publication Date: 26 September 1996 (26.09.96)
---	-----------	--

(21) International Application Number: **PCT/EP96/01244**

(22) International Filing Date: 21 March 1996 (21.03.96)

(30) Priority Data:

08/407,912	21 March 1995 (21.03.95)	US
08/519,203	25 August 1995 (25.08.95)	US

(71) Applicants (for all designated States except US): SANDOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basel (CH). THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10666 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KAJIMOTO, Tetsuya [JP/JP]; 201, Fuji-Haimu, 1-29-37, Shirako, Wako-shi, Saitama 351-01 (JP). WONG, Chi-Huey [US/US]; 6399 Calle del Alcazar, P.O. Box 8154, Rancho Santa Fe, CA 92067 (US).

(74) Common Representative: SANDOZ LTD.; Patent & Trade-mark Division, Lichtstrasse 35, CH-4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published

*With international search report.**Before the expiration of the time limits for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: FUCOPEPTIDES

(57) Abstract

Compounds of formula (I) wherein R is CH₃ and R₁ is a peptidic residue or R₁ is OH and R is a peptidic residue have pharmacological activity as sialyl Lewis X mimetics, e.g. in the prevention or treatment of disorders or diseases which are mediated by the binding of selectins in cellular adhesion.



(I)